Immunoscreening

Immunoscreening is a method of biotechnology used to detect a polypeptide produced from a cloned gene. The term encompasses several different techniques designed for protein identification, such as Western blotting, using recombinant DNA, and analyzing antibody-peptide interactions.[1]

Clones are screened for the presence of the gene product: the resulting protein. This strategy requires first that a gene library is implemented in an expression vector, and that antiserum to the protein is available. Radioactivity or an enzyme is coupled generally with the secondary antibody. The radioactivity/enzyme linked secondary antibody can be purchased commercially and can detect different antigens. In commercial diagnostics labs, labelled primary antibodies are also used.[2] The antigen-antibody interaction is used in the immunoscreening of several diseases.[3]

See also

References

  1. ↑ Razavi, Morteza; Pope, Matthew E.; Soste, Martin V.; Eyford, Brett A.; Jackson, Angela M.; Anderson, N. Leigh; Pearson, Terry W. (2011-02-01). "MALDI immunoscreening (MiSCREEN): a method for selection of anti-peptide monoclonal antibodies for use in immunoproteomics". Journal of Immunological Methods. 364 (1–2): 50–64. doi:10.1016/j.jim.2010.11.001. ISSN 1872-7905. PMC 3018550. PMID 21078325.
  2. ↑ Karam, James (November 26, 1990). Methods in Nucleic Acids Research. CRC Press. p. 309. ISBN 0849353114.
  3. ↑ Mukerjee S, McKnight ME, Glassy MC. Immunoscreening protocols for the identification of clinically useful antibodies and antigens. Expert Opin Investig Drugs. 1998 Mar;7(3):373-89. doi: 10.1517/13543784.7.3.373. PMID 15991979.


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.